Burn victims have few treatment options. Berry Pharmaceuticals exists to change this.
The medical space lacking is treatment options for “burns to the human skin” in both open broken skin and closed skin conditions.
To this end, Berry Pharmaceuticals, LLC focuses on three areas for pharmaceutical development.
We focus on the development of new treatment options for three types of burns on human skin.
Acute Cutaneous Radiation Dermatitis:
Specifically in the field of radiation burns in our society are radiation burns of cutaneous injury from the use of Cobalt 60 in radiotherapy cancer treatments, cutaneous radiation burns from cosmic radiation in outer space for astronauts in travel and habitation, and cutaneous nuclear radiation from explosions and nuclear leakage with nuclear fallout.
Acute and chronic Major Thermal Burns:
Specifically in the field of open burn wounds are thermal, scald, electrical, and chemical burns. The most serious form of injury is full-thickness burns requiring escharotomy (the surgical excision of devitalized tissue down to vitalized tissue) which need urgent skin coverage to avoid burn wound infection.
Acute and Chronic Burn Scar:
Specifically in the field of closed burn wounds that have already undergone re-epithelialization and closure, the biggest issue in Burn Medicine is burn scar, especially related to post-split thickness skin grafting. Human scars are a result of full-thickness injuries such as burns, post-surgical, traumatic, and post-inflammatory such as acne and psoriasis.
We develop drugs to help humans heal
Through innovative medicine, science, and drug development, we have harnessed the power of the rainforest and are developing topical treatments that are the first of their kind.
Value in Innovation
Innovation in Science
The first creation of new value is the topical cure and management for acute cutaneous radiation dermatitis burn back to normal skin, which will be the first FDA-approved topical cure for radiation damage since Madam Curie discovered radioactivity in 1903 as described in the Nobel Prize she was awarded.
Innovation in Medicine
The second creation of new value occurs with the new topical drug to cure and manage open burn wound closure without the use of the 150-year tradition of routine skin grafting in virtually every large full-thickness burn patient.
Innovation in Pharmaceuticals
The third creation of new value is the pharmaceutical topical management to topically revise human scars and improve skin appearance.
“Altruistically helping heal disease for improved quality of life through ethical innovative pharma development.“
Our desired outcomes
If you find our story compelling, contact us to partner in furthering our mission to heal people’s diseases through innovative pharmaceutical development.
A full business plan and presentation are available for qualified investors.